$4.2 Billion is the total value of Cormorant Asset Management, LP's 105 reported holdings in Q4 2020. The portfolio turnover from Q3 2020 to Q4 2020 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| AVIR | New | ATEA PHARMACEUTICALS INC | $259,830,000 | – | 6,411,355 | +100.0% | 6.18% | – |
| QQQ | New | INVESCO QQQ TRput | $235,305,000 | – | 750,000 | +100.0% | 5.60% | – |
| OLMA | New | OLEMA PHARMACEUTICALS INC | $148,169,000 | – | 3,195,544 | +100.0% | 3.53% | – |
| CCCC | New | C4 THERAPEUTICS INC | $80,021,000 | – | 2,490,065 | +100.0% | 1.90% | – |
| BCAB | New | BIOATLA INC | $75,416,000 | – | 2,292,060 | +100.0% | 1.80% | – |
| TARS | New | TARSUS PHARMACEUTICALS INC | $69,965,000 | – | 1,714,269 | +100.0% | 1.66% | – |
| PRAX | New | PRAXIS PRECISION MEDICINES I | $57,739,000 | – | 1,074,145 | +100.0% | 1.37% | – |
| ALGS | New | ALIGOS THERAPEUTICS INC | $34,484,000 | – | 1,267,166 | +100.0% | 0.82% | – |
| MASS | New | 908 DEVICES INC | $29,503,000 | – | 545,322 | +100.0% | 0.70% | – |
| GLTO | New | GALECTO INC | $26,464,000 | – | 2,150,732 | +100.0% | 0.63% | – |
| SBTX | New | SILVERBACK THERAPEUTICS INC | $23,170,000 | – | 500,000 | +100.0% | 0.55% | – |
| NVUS | New | NOVUS THERAPEUTICS INC | $21,363,000 | – | 1,415,500 | +100.0% | 0.51% | – |
| FHTX | New | FOGHORN THERAPEUTICS INC | $20,270,000 | – | 1,000,000 | +100.0% | 0.48% | – |
| NTLA | New | INTELLIA THERAPEUTICS INCput | $16,320,000 | – | 300,000 | +100.0% | 0.39% | – |
| SWTX | New | SPRINGWORKS THERAPEUTICS INC | $9,065,000 | – | 125,000 | +100.0% | 0.22% | – |
| FDMT | New | 4D MOLECULAR THERAPEUTICS IN | $8,290,000 | – | 200,000 | +100.0% | 0.20% | – |
| BLSA | New | BCLS ACQUISITION CORP | $5,513,000 | – | 500,000 | +100.0% | 0.13% | – |
| FVAM | New | 5 01 ACQUISITION CORP | $5,085,000 | – | 500,000 | +100.0% | 0.12% | – |
| REPL | New | REPLIMUNE GROUP INC | $4,769,000 | – | 125,000 | +100.0% | 0.11% | – |
| HLXA | New | HELIX ACQUISITION CORP | $4,742,000 | – | 430,000 | +100.0% | 0.11% | – |
| MGEN | New | MIRAGEN THERAPEUTICS INC | $1,532,000 | – | 93,126 | +100.0% | 0.04% | – |
| CEREW | New | CEREVEL THERAPEUTICS HLDNG I*w exp 06/09/202 | $753,000 | – | 133,331 | +100.0% | 0.02% | – |
| IMV | New | IMV INC | $716,000 | – | 234,374 | +100.0% | 0.02% | – |
| XFOR | New | X4 PHARMACEUTICALS INC | $669,000 | – | 103,980 | +100.0% | 0.02% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-02-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| QUOTIENT LTD | 30 | Q3 2021 | 4.3% |
| ASCENDIS PHARMA A/S | 30 | Q4 2022 | 4.8% |
| MINERVA NEUROSCIENCES INC | 29 | Q3 2021 | 4.4% |
| ACCELERON PHARMA INC | 28 | Q2 2021 | 3.4% |
| OMEROS CORP | 27 | Q3 2021 | 6.5% |
| APELLIS PHARMACEUTICALS INC | 26 | Q1 2024 | 8.6% |
| MIRATI THERAPEUTICS INC | 25 | Q4 2022 | 7.6% |
| BLUEPRINT MEDICINES CORP | 25 | Q3 2021 | 3.6% |
| ROCKET PHARMACEUTICALS, INC | 25 | Q1 2024 | 2.4% |
| NEUROCRINE BIOSCIENCES INC | 24 | Q1 2020 | 4.6% |
View Cormorant Asset Management, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Rapport Therapeutics, Inc. | June 20, 2024 | 1,283,673 | - |
| CytomX Therapeutics, Inc. | May 13, 2024 | 5,750,000 | - |
| TScan Therapeutics, Inc. | April 29, 2024 | 2,500,000 | - |
| Immuneering Corp | April 15, 2024 | 561,128 | - |
| Ventyx Biosciences, Inc. | March 21, 2024 | 3,670,000 | - |
| Corbus Pharmaceuticals Holdings, Inc. | March 18, 2024 | 2,025,000 | - |
| 89bio, Inc.Sold out | February 14, 2024 | 0 | - |
| Aerovate Therapeutics, Inc.Sold out | February 14, 2024 | 0 | - |
| ALPINE IMMUNE SCIENCES, INC. | February 14, 2024 | 2,550,000 | - |
| Ambrx Biopharma, Inc. | February 14, 2024 | 8,725,040 | - |
View Cormorant Asset Management, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-09-24 |
| N-PX | 2024-08-30 |
| 13F-HR | 2024-08-14 |
| SC 13G | 2024-06-20 |
| 4 | 2024-06-13 |
| 13F-HR | 2024-05-15 |
| SC 13G | 2024-05-13 |
| 4 | 2024-05-08 |
| SC 13G | 2024-04-29 |
| 4 | 2024-04-22 |
View Cormorant Asset Management, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.